The Asia Pacific Sequencing Reagents Market is expected to witness market growth of 18.4% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Sequencing Reagents Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.65 billion by 2031. The Japan market is registering a CAGR of 17.7% during 2024-2031. Additionally, the India market is expected to showcase a CAGR of 19.3% during 2024-2031.
The growing incidence of genetic disorders, coupled with the emergence of personalized medicine, serves as a significant catalyst for the sequencing reagents market. Genomic sequencing has established itself as a crucial instrument for the diagnosis and management of complex diseases. In oncology, genomic sequencing helps identify actionable mutations, enabling targeted therapies tailored to a tumor's molecular profile.
Moreover, testing for EGFR mutations in lung cancer determines eligibility for tyrosine kinase inhibitors, while detecting BRCA1 and BRCA2 mutations in breast and ovarian cancer informs the use of PARP inhibitors. Similarly, sequencing has revolutionized the diagnosis of rare genetic conditions like Duchenne muscular dystrophy and Marfan syndrome, offering families much-needed answers and enabling tailored interventions. Sequencing reagents, such as library preparation kits and polymerases, are indispensable for ensuring the accuracy and reliability of these diagnostic processes.
The Asia Pacific region represents a swiftly expanding market for sequencing reagents. Oncology is a major driver of the demand for sequencing reagents across Asia Pacific, as nations increasingly adopt genomic technologies for cancer research and precision medicine. Programs like Genomics Thailand, which aims to sequence 50,000 genomes, and the Korea National Cancer Center Initiative, which is focused on developing personalized treatments, highlight the region’s commitment to cancer genomics. Countries like Singapore have integrated sequencing into clinical oncology, using NGS for tumor profiling to guide targeted therapies. These advancements rely heavily on sequencing reagents optimized for detecting genetic mutations and biomarkers, ensuring accurate and reliable data critical for improving cancer outcomes in the region.
The China market dominated the Asia Pacific Sequencing Reagents Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.65 billion by 2031. The Japan market is registering a CAGR of 17.7% during 2024-2031. Additionally, the India market is expected to showcase a CAGR of 19.3% during 2024-2031.
The growing incidence of genetic disorders, coupled with the emergence of personalized medicine, serves as a significant catalyst for the sequencing reagents market. Genomic sequencing has established itself as a crucial instrument for the diagnosis and management of complex diseases. In oncology, genomic sequencing helps identify actionable mutations, enabling targeted therapies tailored to a tumor's molecular profile.
Moreover, testing for EGFR mutations in lung cancer determines eligibility for tyrosine kinase inhibitors, while detecting BRCA1 and BRCA2 mutations in breast and ovarian cancer informs the use of PARP inhibitors. Similarly, sequencing has revolutionized the diagnosis of rare genetic conditions like Duchenne muscular dystrophy and Marfan syndrome, offering families much-needed answers and enabling tailored interventions. Sequencing reagents, such as library preparation kits and polymerases, are indispensable for ensuring the accuracy and reliability of these diagnostic processes.
The Asia Pacific region represents a swiftly expanding market for sequencing reagents. Oncology is a major driver of the demand for sequencing reagents across Asia Pacific, as nations increasingly adopt genomic technologies for cancer research and precision medicine. Programs like Genomics Thailand, which aims to sequence 50,000 genomes, and the Korea National Cancer Center Initiative, which is focused on developing personalized treatments, highlight the region’s commitment to cancer genomics. Countries like Singapore have integrated sequencing into clinical oncology, using NGS for tumor profiling to guide targeted therapies. These advancements rely heavily on sequencing reagents optimized for detecting genetic mutations and biomarkers, ensuring accurate and reliable data critical for improving cancer outcomes in the region.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.Illumina, Inc.
Market Report Segmentation
By Type
- Sequencing Kits
- Library Kits
- Control Kits
- Template Kits
- Other Type
By Technology
- Next-Generation Sequencing
- Third Generation Sequencing
- Sanger Sequencing
By Application
- Oncology
- Reproductive Health
- Clinical Investigation
- Agrigenomics & Forensics
- Consumer Genomics
- Other Application
By End Use
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Other End Use
By Country
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Sequencing Reagents Market by Type
Chapter 6. Asia Pacific Sequencing Reagents Market by Technology
Chapter 7. Asia Pacific Sequencing Reagents Market by Application
Chapter 8. Asia Pacific Sequencing Reagents Market by End Use
Chapter 9. Asia Pacific Sequencing Reagents Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
- Illumina, Inc.
Methodology
LOADING...
